Cassava Sciences (SAVA) fell ~14% in the premarket on Friday after the company said it will be forced to delay a clinical trial for its lead candidate, simufilam, for a form of epilepsy, as it moves ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The settlement comes after years ...

Cassava Sciences ( (SAVA)) has provided an update. Between August 27 and October 26, 2021, four putative federal securities class actions were filed against Cassava Sciences and certain officers in ...

AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ...

Cassava Sciences (SAVA) announced on Thursday that the Fraud Section of the U.S. Department of Justice has closed an investigation into the company over allegations related to its research misconduct.

Where the field convenes. Privately. A curated private community for credentialed ethics, risk, and compliance leaders across the ECI and Compliance Week network. Ask the questions you can’t post ...

Nike recorded a lower profit and said it expects revenue to a decline in its current quarter. The stock fell 11% to $58.62 in after-hours trading Thursday. Cassava Sciences said the FDA had placed a ...